Document is current
Any future updates will be listed below
-
Authors
Woolpert, Kirsten M.
Ahern, Thomas P.
Baurley, James W.
Maliniak, Maret L.
Damkier, Per
Kjærsgaard, Anders
Collin, Lindsay J.
Hamilton-Dutoit, Stephen
Tramm, Trine
Ejlertsen, Bent
Sørensen, Henrik T.
Lash, Timothy L.
Cronin-Fenton, Deirdre P.
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R360-A21289, R327-A19070)
National Cancer Institute (K99CA277580, R01CA166825)
Danmarks Frie Forskningsfond (DFF-1030-00052B)
Novo Nordisk Fonden (NNF19OC0058710)
Aarhus Universitet
- License Information
-
More Information
Article History
Received: 28 January 2025
Accepted: 2 May 2025
First Online: 14 May 2025
Declarations
:
: LJC reports personal fees from Epidemiologic Research & Methods, LLC outside of the submitted work. TLL is a member of the Amgen Methods Advisory Council, for which he receives consulting fees and travel support. This work is outside of the submitted work. BE reports outside the submitted work an Advisory Role: Eli Lilly; Research funding: Institutional grants from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen; and Travel, Accommodations, Expenses: Daiichi Sankyo, MSD, and Pfizer. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants, unrelated to the current study. All other authors have no disclosures.
